**Supplemental Digital Content 11: Ocular and nonocular adverse events up to month 12 suspected to be related to the study drug treatment (Safety set\*)**

|  |  |  |  |
| --- | --- | --- | --- |
| **Preferred term, n (%)** | **Ranibizumab 0.5 mg (n = 119)** | **Sham with ranibizumab 0.5 mg (n = 52)** | **Total(N = 178)** |
| **Ocular AEs, total** | **2 (1.7)** | **1 (1.9)** | **3 (1.7)** |
| Retinal cyst | 1 (0.8) | 0 | 1 (0.6) |
| Vitreous floaters | 1 (0.8) | 0 | 1 (0.6) |
| RPE tear | 0 | 1 (1.9) | 1 (0.6) |
| IOP increased | 1 (0.8) | 0 | 1 (0.6) |
| **Nonocular AEs, total** | **1 (0.8)** | **0** | **1 (0.6)** |
| Arrhythmia | 1 (0.8) | 0 | 1 (0.6) |
| Blood pressure increased | 1 (0.8) | 0 | 1 (0.6) |
| \*Consisted of all adult patients who received at least one application of study treatment and had at least one post-baseline safety assessment.No AEs were reported for patients in the sham without ranibizumab group.Preferred terms are sorted in descending order of frequency of the ranibizumab 0.5 mg group. A patient with multiple occurrences of a preferred term was counted only once in the preferred term row. AE, adverse event; IOP, intraocular pressure; RPE, retinal pigment epithelium |